Navigation Links
Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
Date:6/3/2008

4 or more cycles (4 week cycle)

Antitumor activity and toxicity were similar between the Injection and Injectable Suspension products.

-- Of the 31 patients enrolled, 21 were treated with Kosan's Injection

product (Cremophor(R)-containing formulation and 10 were treated with

Kosan's Injectable Suspension product (contains no Cremophor). In

addition, 4 of the patients treated initially with the Injection

formulation crossed over to receive the Injectable Suspension

formulation.

-- For the Injection product: 18 were evaluable and 11 responded

(4 PR, 4 tumor regressions, 3 SD), yielding a PR response rate of

22% and a clinical benefit incidence of 61%.

-- For the Injectable Suspension product: 9 were evaluable and 6

responded (3 PR, 1 tumor regression, 2 SD), yielding a PR response

rate of 33% and a clinical benefit incidence of 67%.

-- Patients with an objective response on the Injection product

maintained their objective response after crossover to the

Injectable Suspension product.

Tanespimycin plus trastuzumab was highly tolerable at the recommended Phase 2 dose of 450 mg/m2 weekly. Common toxicities were mainly mild-to-moderate diarrhea, fatigue, nausea, headache and vomiting (limited duration and amenable to supportive care). The few drug-related Grade 3 and 4 toxicities (including fatigue, increased AST and headache, two patients each) were manageable and only one patient discontinued treatment for an adverse event. Noticeably absent were toxicities common to cytotoxic chemotherapy including alopecia and myelosuppression. The Injectable Suspension product provided considerable advantages over the Injection product, including shorter time of infusion, no need for steroid or antihistamine premedications and ease of pharmacist preparation.

Kosan anticipates conducti
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
2. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
3. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
4. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
7. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
8. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
9. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
10. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
11. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Medical, Inc. (Nasdaq: AEMD ), today announced that ... the Rodman & Renshaw 17th Annual Global Investment Conference in ... ET on Thursday, September 10, 2015. The presentation ... webcast which can be accessed by visiting the investor relations ... The webcast will be archived for thirty days.  ...
(Date:9/2/2015)... , Sept. 2, 2015  RegeneRx Biopharmaceuticals, ... clinical-stage drug development company focused on tissue protection, ... Finkelstein , President and Chief Executive Officer, will ... Renshaw Global Investment Conference, sponsored by H.C. ... held September 8-10, 2015 at the St. Regis ...
(Date:9/2/2015)... MENLO PARK, Calif. , Sept. 2, 2015 ... company today announced that Jim Pekarsky , chief executive ... & Renshaw 17th Annual Global Investment Conference taking place, September ... York . Mr. Pekarsky is scheduled to ... in Astor Suite A (2 nd floor). ...
Breaking Medicine Technology:RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3
... Dec. 6, 2011 The US Oncology Network announced ... York Oncology Hematology , and J. Russell Hoverman , M.D., ... on value-based reimbursement and its impact on the future of cancer ... 1:00 p.m. ET/ 12 p.m. CT/ 11 a.m. MT/ 10 a.m. ...
... Chairman, Mr. E. Thomas Arington, announced today that Mr. ... and chief executive officer of Prasco.  He also announced ... chief operating officer, Mr. David Furniss as chief financial ... ventures. "I am extremely pleased to ...
Cached Medicine Technology:The US Oncology Network to Present Webinar on Value-Based Reimbursement 2Prasco Announces New, Expanded Roles for Key Executives 2
(Date:9/2/2015)... ... September 02, 2015 , ... RxNT , an innovative ... its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone app ... A leader in health technology, RxNT was one of the first to build ...
(Date:9/2/2015)... ... September 02, 2015 , ... Healtec® LLC hired ... departure of Kristen Dietz, former Chief Operations Officer. Shaun Carpenter MD, FAPWCA, ... welcoming Mr. Salot: “ Stanley H. Salot Jr , our new President and ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... its latest addition to its screen mirroring and extending product line -- ... Display, which operates in local WIFI setting, the new Splashtop Wired XDisplay delivers ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... a large stream of mixed documents that include EOBs, payments, and payment related ... extracting the data needed to reconcile their billing, with one efficient process and ...
(Date:9/2/2015)... ... September 02, 2015 , ... Density measurement ... final products. Automating sample handling makes density measurements more efficient and error-free. The ... of the automated workflow and the advantages compared to manual sample handling. , ...
Breaking Medicine News(10 mins):Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:Healtec® Announces Executive Leadership Change 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3
... Today, Tuesday, January 27, 2009, 9:30 A.M.** Elected ... Community Based Health System for Embracing Courageous New Direction ... Accord Includes Free and Fair Union ... Conference to announce historic hospital accords. WHEN: Today, ...
... seize billions from state, construct prison health care centers ... lawsuit was filed this week to prevent a federal ... dollars from California,s treasury for the sole purpose of ... Safe Ventura County opposes the proposal to construct seven ...
... Fitness Industry Leader Champions Gupta,s Commitment to Enriching Quality ... 27 The American Council on Exercise (ACE), America,s ... fitness certification, education and training organizations in the world, ... Dr. Sanjay Gupta , chief medical correspondent for the ...
... (NYSE: SGP ) today reported that it ... study, a pivotal Phase III study in treatment-naive patients. ... III study in patients who failed prior treatment that ... enrolled its registration studies for boceprevir, its lead investigational ...
... (NYSE Alternext US: ILI) today announced that the Company has ... "Exchange") that outlines the Company,s strategy to regain compliance with ... Exchange to formally respond to the submitted plan within 45 ... able to continue its listing up to June 23, 2010 ...
... ANTHEM, Ariz., Jan. 27 Prime Companies, Inc. ... , The Company has begun receiving income ... , The web site is now accessible ... , , "These are major achievements and ...
Cached Medicine News:Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 2Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 3Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 4Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 5Health News:Caritas Christi, 1199SEIU, Area Trades Council to Announce Historic New Accord to Improve Health Care for Community, Patients, Health Workers 6Health News:Ventura County Taxpayers' Group Files Suit to Stop State-of-the-Art Hospitals for Incarcerated Felons 2Health News:American Council on Exercise (ACE) Endorses Appointment of Dr. Sanjay Gupta as Surgeon General of the United States 2Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 2Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 3Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 4Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 5Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 6Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 7Health News:Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients 8Health News:Interleukin Genetics' Submits Plan to Regain Compliance with Continued Listing Standards 2Health News:Prime Companies Revenue Stream Begins; Dentists in Every City and Town Available on Company's New Web Site 2
Expressions lets you change your eye color with lenses that offer incredible comfort and outstanding vision quality. Expression color lenses use a technologically advanced tinting process to produce ...
Modern, innovative and quick Intense Pulsed Light system. The Flash 1 is light and very compact, thus easily portable. Available in two different colors....
... for the physician who wishes to offer ... of clinical applications. The innovative cooled Nd:YAG ... treaent of deeper lying veins. The IPL ... and pigmented lesions, including IPL Skin Treaents ...
Available in Purple, orange, dark blue, yellow, gray, royal blue, green and light blue colors....
Medicine Products: